Otilimab ELISA Kit

Catalog No.

KDC06703

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CSF2 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Otilimab in the sample competitively binds to the pre-coated protein with biotin-labeled Otilimab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Otilimab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Otilimab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

125 - 8,000 ng/mL

Sensitivity

80.29 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	4393.1	1025.1	323.1	3625.9	871.8	312.0
Standard deviation	248.5	117.1	56.2	234.9	73.4	48.0
CV (%)	5.7	11.4	17.4	6.5	8.4	15.4

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

MOR-04357, 3196165, GSK3196165, MOR103, CAS: 1638332-55-4

Background

Otilimab is an IgG1 mAb that binds to GM-CSF and hinders its interaction with GM-CSFRα; it was developed by Morphosys AG (MOR-103) and then sublicensed to GSK (GSK3196165) to conduct large-scale clinical trials.

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)., PMID:40044198

Meaningful score changes for SF-36v2, FACIT-fatigue, and RASIQ in rheumatoid arthritis., PMID:38252223

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)., PMID:37699654

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)., PMID:37696589

Severe SARS-CoV-2 Pneumonia and Pneumomediastinum/Pneumothorax: A Prospective Observational Study in an Intermediate Respiratory Care Unit., PMID:37306158

GM-CSF targeting in COVID-19: an approach based on fragile foundations., PMID:36396141

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)., PMID:36229048

A guide to immunotherapy for COVID-19., PMID:35064248

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study., PMID:38279364

MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study., PMID:38279363

Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial., PMID:38273625

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis., PMID:32033937

Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects., PMID:31486005

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial., PMID:24534756

Document Download

Otilimab ELISA Kit.pdf